Conservative treatment for atypical endometrial hyperplasia: What is the most effective therapeutic method?

Journal of Gynecologic Oncology

Volumn 25, Issue 3, 2014, Pages 164-165

  Kim, Mi Kyoung ^a   Seong, Seok Ju ^a  

^a CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METFORMIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK FACTOR; TREATMENT FAILURE; WEIGHT REDUCTION; ENDOMETRIAL HYPERPLASIA;

ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MEGESTROL ACETATE; METFORMIN;

EID: 84904606013     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2014.25.3.164     Document Type: Editorial

References (16)

1. Anastasiadis PG, Skaphida PG, Koutlaki NG, Galazios GC, Tsikouras PN, Liberis VA. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol 2000;21:131-4.
2. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547.e1-10.
3. Lee TS, Seong SJ, Kim JW, Ryu HS, Song ES, Nam BH. Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006). Jpn J Clin Oncol 2011;41:817-9.
4. Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol 2010;21:102-5.
5. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia: a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-75.
6. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210-3.
7. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73.
8. Abu Hashim H, Zayed A, Ghayaty E, El Rakhawy M. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial. J Gynecol Oncol 2013;24: 128-34.
9. Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 2014; 121:477-86.
10. Shan W, Wang C, Zhang Z, Gu C, Ning C, Luo X, et al. Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia. J Gynecol Oncol 2014;25:214-20.
11. Session DR, Kalli KR, Tummon IS, Damario MA, Dumesic DA. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol 2003;17:405-7.
12. Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112(2 Pt 2):465-7.
13. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803.
14. Lin J, Li R, Zhou J. The influence of insulin on secretion of IGF-I and IGFBP-I in cultures of human endometrial stromal cells. Chin Med J (Engl) 2003;116:301-4.
15. Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol 2012;124:542-8.
16. UNC Lineberger Comprehensive Cancer Center. Metformin with the levonorgestrel-releasing intrauterine device for the treatment of complex atypical hyperplasia (CAH) and endometrial cancer (EC) in non-surgical patients (clinical trial.gov identifier: NCT 02035787) [Internet]. 2014 [cited 2014 Jun 18]. Available from: http://clinicaltrials.gov/show/NCT02035787.